Asset Details
Do you wish to reserve the book?
OP42 Pharmacokinetic characteristics of liposomal bupivacaine and mixture of liposomal bupivacaine and plain bupivacaine
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
OP42 Pharmacokinetic characteristics of liposomal bupivacaine and mixture of liposomal bupivacaine and plain bupivacaine
Do you wish to request the book?
OP42 Pharmacokinetic characteristics of liposomal bupivacaine and mixture of liposomal bupivacaine and plain bupivacaine
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
OP42 Pharmacokinetic characteristics of liposomal bupivacaine and mixture of liposomal bupivacaine and plain bupivacaine
2025
Overview
Background and AimsLiposomal bupivacaine (LB) is becoming an important drug for postoperative analgesia and has the potential to increase nerve block duration for up to 72 as the encapsulated bupivacaine is slowly released over time. However, LB may not provide adequate immediate postoperative analgesia. Several studies have shown that mixture of liposomal bupivacaine and plain bupivacaine (Mix) may provide immediate and enduring analgesia, but the pharmacokinetic characteristics have not been assessed.MethodsTo compare the pharmacokinetic profile and tolerability of liposomal bupivacaine and mixture of liposomal bupivacaine and plain bupivacaine, male rats aged 6–8 weeks were selected to receive either LB or Mix by subcutaneous injection and plasma pharmacokinetic profiles were assayed by Liquid Chromatography with tandem mass spectrometry.The present study was approved by the local ethical committee.ResultsThe analysis showed that compare with LB, Mix possessed higher Cmax (2418.33±373.48 ng/ml vs. 281.13±71.54 ng/ml), shorter Tmax (0.17±0.01 h vs. 0.30± 0.21 h), higher AUC0-t (5293.08±307.20 h ng/ml vs. 1414.13±278.33 h ng/ml) and AUC0-∞ (5448.86±311.72 h ng/ml vs. 1469.19±279.80 h ng/ml), but shorter MRT0-∞(9.33±1.15 h vs. 7.17±0.72 h)(table 1, figure 1).Abstract OP42 Figure 1Concentration-time curve of LB and Mix. (a) Concentration-time curve of LB; (b) Concentration-time curve of mix[Image Omitted. See PDF.]Abstract OP42 Table 1Pharmacokinetic characteristics of LB and Mix in rats (n=3)[Image Omitted. See PDF.]ConclusionsThis study is the first to focus on the pharmacokinetic characteristics of LB and Mix in rodent. Our results showed that Mix exhibited shorter time to peak and higher plasma concentrations, but the analgesia duration may reduce as compared to LB. The study was perfoemed in rats, it may differ from human patients, further study was needed to testify the clinical efficacy of mixture of liposomal bupivacaine and plain bupivacaine.
Publisher
BMJ Publishing Group LTD
Subject
We currently cannot retrieve any items related to this title. Kindly check back at a later time.